Danaher (DHR) Offering Possible 23% Return Over the Next 27 Calendar Days

This article was originally published on this site

Danaher’s most recent trend suggests a bearish bias. One trading opportunity on Danaher is a Bear Call Spread using a strike $165.00 short call and a strike $175.00 long call offers a potential 23% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $165.00 by expiration. The full premium credit of $1.87 would be kept by the premium seller. The risk of $8.13 would be incurred if the stock rose above the $175.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Danaher is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Danaher is bearish.

The RSI indicator is at 41.79 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Danaher

Danaher Luxembourg Finance S.a.r.l. — Moody’s announces completion of a periodic review of ratings of Danaher Corporation
Tue, 19 May 2020 14:57:11 +0000
Moody’s Investors Service (“Moody’s”) has completed a periodic review of the ratings of Danaher Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody’s reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

Beckman Coulter launches DxH 690T mid-volume hematology analyzer, featuring the Early Sepsis Indicator in U.S. market
Mon, 18 May 2020 15:49:00 +0000
Beckman Coulter announced today the availability of its DxH 690T hematology analyzer in the U.S. Designed to streamline workflow and minimize downtime in mid-volume laboratories, the DxH 690T delivers all of the benefits of the company’s flagship DxH 900 large-volume hematology analyzer in a table-top configuration.

A Trio of Strong Performers to Consider
Mon, 18 May 2020 15:28:48 +0000
They have recently beat the S&P; 500 Continue reading…

Merck, Medtronic, and Other Health-Care Stocks Widely Owned by ESG Funds Outperform
Sat, 16 May 2020 13:15:00 +0000
Health-care stocks that were popular in ESG funds tended to score better on ESG issues than other stocks in the sector in conventional funds, according to a study.

Is Danaher Stock a Buy?
Fri, 15 May 2020 12:18:00 +0000
The life sciences and diagnostics company is likely to see increased demand for its solutions after the COVID-19 pandemic has been contained.

Be Sociable, Share!

Related Posts